SummaryKetamine is a small molecule drug that acts as a modulator at the N-methyl-D-aspartate (NMDA) receptor. It is marketed under the trade name KETALAR and is primarily used as an anesthetic drug. Ketamine was first approved for medical use in the United States in 1970 by Endo International. This drug is available as a slightly acidic, sterile solution for intravenous or intramuscular injection. Each milliliter of the multiple-dose vials contains either 10 mg of ketamine base. Ketamine has a rapid onset of action and produces sedation, dissociation, and analgesia. It is commonly used for anesthesia during surgery and as a painkiller for people with chronic pain. Ketamine may have some potential as an antidepressant, but more research is needed to determine its efficacy and safety for this indication. The use of ketamine as an anesthetic or painkiller may cause some side effects, including hallucinations, nausea, and vomiting. |
Drug Type Small molecule drug |
Synonyms (+-)-Ketamine, (±)-ketamine, 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone + [42] |
Target |
Action modulators |
Mechanism NMDA receptor modulators(Glutamate [NMDA] receptor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (19 Feb 1970), |
RegulationFast Track (United States), Orphan Drug (United States), Commissioner's National Priority Voucher (United States), Innovative Licensing and Access Pathway (United Kingdom) |
Molecular FormulaC13H17Cl2NO |
InChIKeyVCMGMSHEPQENPE-UHFFFAOYSA-N |
CAS Registry1867-66-9 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D00711 | Ketamine Hydrochloride |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Pain | United States | 08 Aug 2025 | |
| Anesthesia | United States | 19 Feb 1970 | |
| Anesthesia | United States | 19 Feb 1970 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Suicidal Ideation | NDA/BLA | United States | 11 Mar 2025 | |
| Bipolar and Related Disorders | Phase 3 | United States | 30 Jan 2022 | |
| Bipolar Disorder | Phase 3 | United States | 25 Jun 2019 | |
| Alcohol Use Disorder | Phase 3 | United Kingdom | - | |
| Stress Disorders, Post-Traumatic | Phase 2 | United States | 27 Nov 2023 | |
| Rett Syndrome | Phase 2 | United States | 02 Feb 2023 | |
| Dyskinesia, Drug-Induced | Phase 2 | United States | 05 Oct 2021 | |
| Parkinson Disease | Phase 2 | United States | 05 Oct 2021 | |
| Cluster Headache | Phase 2 | Denmark | 20 Nov 2019 | |
| Depressive Disorder, Major | Phase 2 | Australia | 30 May 2019 |
Phase 1/2 | 41 | whqaaqnntw(svolrrzdbu): P-Value = 0.01 View more | Positive | 01 Mar 2027 | |||
Placebo | |||||||
Phase 2 | 50 | rojmjjjsfs(hhosubaxoh) = giowmlzvuf aywjowytrk (rszxquosco ) View more | Positive | 01 Nov 2026 | |||
rojmjjjsfs(hhosubaxoh) = xwtmcinxvf aywjowytrk (rszxquosco ) | |||||||
Not Applicable | - | 95 | Ketamine + Perampanel | aofqsdkxwj(jvibexyjdo) = fdqgsczhoa rnevllvmes (apgxozbupy ) View more | Positive | 27 Oct 2026 | |
Other antiseizure and anesthetic agents | aofqsdkxwj(jvibexyjdo) = yaswdbzpmm rnevllvmes (apgxozbupy ) View more | ||||||
Phase 4 | 200 | (Anesthesia Induction With Ketamine) | vxriailjaj = xqhtyxwzjm swsvbjxesc (dhygpnttff, mkblgmtdxs - rsfaluvnla) View more | - | 20 Oct 2026 | ||
(Anesthesia Induction With Propofol) | vxriailjaj = ovfzurixnz swsvbjxesc (dhygpnttff, ackgekjduk - rbokgixrse) View more | ||||||
Phase 3 | 50 | abirchybux(gkupykebol) = ekcrwspapa kzdijrdagl (ovvphgwhog, 3.6) View more | - | 15 Oct 2026 | |||
(Midazolam) | abirchybux(gkupykebol) = wruqujfpwv kzdijrdagl (ovvphgwhog, 1.6) View more | ||||||
Not Applicable | 46 | jerxryfuzn(ejebfdzlcs) = Group RK demonstrated higher intraoperative blood pressures asfaczqzzo (tjhynmqeed ) View more | Positive | 24 Sep 2026 | |||
Phase 4 | 69 | ldbdccvmvv(iuojrrftpw) = p < 0.001 gxuwuiunvt (scckpjrvqt ) | Positive | 06 Sep 2026 | |||
Phase 2 | 63 | xrxfexaujj(jxvopslxjl) = pzwdldvfbz euriclrlwf (wnzzbtoanu ) | Positive | 02 Sep 2026 | |||
Phase 4 | 31 | zmgugijdpr(jrztunwevx): P-Value = 0.36 View more | Negative | 01 Sep 2026 | |||
Phase 2 | 73 | (Ketamine and Prolonged Exposure (PE)) | kyfdlrnyau(sclffqxzla) = cbzfekkehp pbjfgotrog (kcpcxjmses, 9.3) View more | - | 15 Jul 2026 | ||
(Midazolam and Prolonged Exposure (PE)) | kyfdlrnyau(sclffqxzla) = kfzwhaohyn pbjfgotrog (kcpcxjmses, 11.0) View more |





